PCI Research News

Piedmont Cancer Institute (PCI), well-known for high standards in patient care, has excelled in offering patients the latest clinical trials. The doctors and staff at PCI are engaged in 20 clinical trials and continue investigating a broad spectrum of cutting edge and treatment strategies.  According to Dr. Rajni Sinha, a principal investigator at PCI, “we are staying at the forefront of cancer treatment by developing innovative strategies which gives us insight into cancer”.

Piedmont Cancer Institute, with Dr. Trevor Feinstein as principal investigator, completed a clinical trial in extensive stage small cell lung cancer utilizing carboplatin, etoposide, atezolizumab with and without trilaciclib. The trial led to trilaciclib’s FDA approval as the first and only myeloprotective therapy to decrease the incidence of chemotherapy induced myelosuppression. 

Recently, Piedmont Cancer Institute presented a pooled analysis from 3 randomized trials utilizing trilaciclib in the Journal of Cancer Medicine, Cancer Med. 2021;00:1– 9. https://doi.org/10.1002/cam4.4089. Together with MD Anderson, Thomas Jefferson University, Hungary, and Spain, we demonstrated trilaciclib prior to chemotherapy reduced the need for supportive care.

Katie Adams PCI Research Manger stated “It’s a great honor that we conduct clinical trials with such high standards and employ a research team that always goes above and beyond for our patients. I am proud that our research team at PCI, consisting of coordinators and regulatory, offering over 52 years of combined experience in managing clinical trials.”

“It is PCI’s mission to exceed conventional understanding and treatment methodologies of cancer by utilizing the most advanced, personalized therapies available - with compassionate care throughout” commented Research Director Dr. Vasily Assikis. Our research team takes great pride in exceeding the rigorous standards involved with clinical trials to bring the best care to our patients. For more information regarding clinical trials at PCI please contact 678-298-3235.

Piedmont Cancer Institute Dr. Trevor Feinstein presented to a global audience on June 25, 2021, concerning unmet medical need in treating patients with non-small cell lung cancer (NSCLC) and patients who failed checkpoint inhibitors. Dr. Feinstein joined Steven Lin, M.D. from M.D. Anderson in discussing the current treatment landscape of non-small cell lung cancer and the need for to think outside the box.

Dr. Feinstein’s talk provided an update on plinabulin’s data in NSCLC. He is the principal investigator of the DUBLIN-3 trial with studied Plinabulin in advanced NSCLC as second- or third-line therapy. Dr. Feinstein indicated the hour-long virtual conference was a success and many questions were asked regarding the progress to combat lung cancer. Dr. Assikis, the Director of Research at Piedmont Cancer Institute, says that "We are very proud of Dr. Feinstein’s hard work and dedication in the field of research.  I have never seen someone so committed to helping patients throughout the metro Atlanta areas by providing excellent cancer care.  It is our mission to exceed conventional understanding and treatment methodology of cancer by using the most advanced, personalized therapies available - always putting the patient first."

Dr. Feinstein is the recipient of numerous honors and awards. Dr. Feinstein is a Diplomate of the American Board of Medical Oncology and the American Board of Hematology. He holds memberships with the American Society of Clinical Oncology and Georgia Society of Clinical Oncology.

Dr. Feinstein is located in our Fayetteville office and appointments are available by calling 678-829-1060.

Learn More

From left to right are Tevor Feinstein, MD, Medical Director of Oncology Research at Piedmont Fayette, Geetha Rao, MD, Medical Director of Radiation Oncology at Piedmont Fayette, and Allison Wellons, Research Nurse for Piedmont Fayette.

In a recent article from “The Citizen – Health Wize” Piedmont Cancer Institute’s Dr. Trevor Feinstein was asked about the recent approval of Piedmont Fayette Hospital affiliation for NRG Oncology research studies.   What this means is that Piedmont Fayette Hospital can now have eligible patients participate in clinical research trials. NRG Oncology is the combination of three organizations committed to research in the areas of breast, bowel cancer, radiation therapy, and gynecologic oncology.

“Earning this affiliation proves that Piedmont Fayette has the right infrastructure in place to provide the right data and help make significant contributions to these studies,” said Trevor Feinstein, M.D., Medical Director of Oncology Research at Piedmont Fayette. Dr. Feinstein has work tirelessly to make sure that the programs necessary were available at Piedmont Fayette Hospital.   Research clinical trials seek to answer important questions in cancer treatment.  Areas like immunotherapy for rare cancers, reducing radiation therapy in treatment of some cancers, and the viability of chemotherapy to avoid surgery in some breast cancers is underway.

Patients are not automatically enrolled into clinical trials.  They must meet the strict eligibility criteria, requirements, and all treatments in a clinical trial(s) is optional for patients.  However, because of clinical trials, current patients may benefit from others participating in trials at different locations. Through efforts of our research team we can make strides in seeking better methods of treatments for our patients.

Dr. Feinstein is the recipient of numerous honors and awards. Dr. Feinstein is a Diplomate of the American Board of Medical Oncology and the American Board of Hematology. He holds memberships with the American Society of Clinical Oncology and Georgia Society of Clinical Oncology.

For more information about clinical trials please call 678-829-1060. Dr. Feinstein sees patients in in our Fayetteville  clinic. To make an appointment with Dr. Feinstein or any of our physicians, please call 678-829-1060.